久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

上海非利加實(shí)業(yè)有限公司Logo

熱門詞: 進(jìn)口電動溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動高溫調(diào)節(jié)閥-德國進(jìn)口電動高溫法蘭調(diào)節(jié)閥進(jìn)口電動蒸汽調(diào)節(jié)閥-德國進(jìn)口電動蒸汽調(diào)節(jié)閥

當(dāng)前位置: 首頁 > 所有品牌 > PopGenTech
PopGenTech
PopGenTech PopGenTech

美國PopGenTech
Population Genetics Technologies公司通過多組個體基因組的同步分析,生產(chǎn)可加速大規(guī)模群體研究的產(chǎn)品,諾貝爾獎得主Dr.SydneyBrenner是本公司的聯(lián)合創(chuàng)始人。我們的專利技術(shù)取代了原先的樣本準(zhǔn)備步驟,成為下一代的DNA測序技術(shù),它克服了禁錮發(fā)現(xiàn)的成本障礙和實(shí)踐約束。

The goal of developing personalised medicine is dependent on identifying individuals that are likely to benefit from treatment with a particular drug.
To achieve this, clinicians and pharmaceutical companies need a system for the rapid discovery of clinical biomarkers, such as genetic variants, that are associated with disease predisposition and drug efficacy or toxicity.

Clinical biomarkers are genetic signposts that point to our potential individual drug responsiveness or disease predisposition. These are frequently hidden among millions of insignificant gene variants. Simplistic predictions of a new age of personalised medicine, driven mainly by faster sequencing technology, underestimate the resource required to identify new clinical biomarkers.


Next generation sequencing companies are constantly increasing the speed of sequencing, however the value lies in understanding what sequencing results mean. Faster sequencing will make more studies feasible, but this will not identify individuals that might respond well to a drug or who are likely to develop a particular disease. Indeed, even if sequencing were free, these problems would not be solved.

We are addressing these problems using our unique proprietary technology, in combination with a tailored expert service offering, which enables large-scale genetic analysis to be conducted. By enabling researchers to accurately link genetic variation and disease manifestation or drug response, we will make it possible for healthcare providers to tailor their approaches for specific diseases at the level of the individual. This will drive the introduction of personalised medicine and facilitate the development of cost-effective healthcare approaches.

Population Genetics Technologies now provides an integrated and cost-effective route to genetic biomarker identification, accessible to both commercial and academic organisations. This ground-breaking approach represents a leap forward in the realisation of personalised medicine, as it will enable genetic variation to be accurately linked with phenotype.

Our potential has already been recognised
In 2005, PGT received a Strategic Translation Award from the Technology Transfer Fund at the Wellcome Trust, in recognition of our technology’s potential. In February 2008, following successful demonstration of our key technologies, we raised £3.8 million in venture capital funding to test the combination of these technologies in integrated workflows and to validate their use with small population samples. In May 2009, we received further investment in response to the successful scale-up and achievement of our commercialisation milestones. We have now established a number of academic and commercial collaborations and are seeking to build on these in order to maximise the potential of our commercial offerings.

 

關(guān)于我們客戶服務(wù)產(chǎn)品分類法律聲明
主站蜘蛛池模板: 欧美日韩国内 | 国产精品久久久久9999小说 | 欧美影欧美影院免费观看视频 | 国产精品久久久久国产精品 | 欧美亚洲三级 | 欧洲亚洲欧美国产日本高清 | 国产在线欧美日韩一区二区 | 欧美日韩大尺码免费专区 | 日韩精品在线第一页 | 欧美精品午夜久久久伊人 | 亚欧美色 | 一道本一区二区三区 | 日韩有码在线播放 | 999久久久免费精品国产牛牛 | 国产高清在线 | 国产一区二区福利久久 | 久久亚洲精品中文字幕60分钟 | 日本不卡视频一区二区三区 | 亚洲欧美色图 | 一级毛片特黄久久免费看 | er久99久热只有精品国产 | 国产在线精品一区二区夜色 | 国产在线不卡视频 | 久久精品国产一区二区三区 | 久久精品一区二区三区不卡牛牛 | 狼人综合伊人 | 国产精品亚洲欧美一区麻豆 | 国产高清一区二区 | 欧美色图亚洲天堂 | 欧美一区二区在线 | 中文字幕另类 | 久久久久成人精品一区二区 | 欧美精品一区二区三区免费播放 | 日本一区二区三区高清在线观看 | 在线欧美日韩制服国产 | 日韩va亚洲va欧美va浪潮 | 国产淫语打电话对白在线播放 | 国产成人不卡亚洲精品91 | 国产一区二区精品久久91 | 欧美日韩国产成人精品 | 久久综合精品国产一区二区三区无 |